
Sedana Medical's Sedaconda Study Awarded at DGIIN & ÖGIAIN



Sedana Medical AB (publ) today announced that the company's pivotal phase III study Sedaconda (SED001) has been named one of the three best posters at the 52nd intensive care conference DGIIN & ÖGIAIN 16–18 June 2021.

"It is very positive that the Sedaconda study is receiving this attention in Germany, which is our largest market. The strong study results form the basis for our ongoing market application and if all goes well, we expect to be able to launch the treatment inhaled sedation in Europe during the second half of this year," said Jens Lindberg, Acting CEO of [Sedana Medical](#).

DGIIN & ÖGIAIN is the joint annual meeting of the German and Austrian emergency medicine and intensive care societies.

Published on : Tue, 22 Jun 2021